Recent Updates
Recently added Catalysts
SYK Positive Sentiment Score: 85/100

Stryker completes acquisition of Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio

Key Takeaway: Stryker has completed the acquisition of Amplitude Vascular Systems, enhancing its peripheral vascular portfolio with next-generation intravascular lithotripsy technology. This acquisition is expected to improve treatment for complex peripheral arterial disease. Stryker aims to leverage AVS's innovative technology to better support physicians and patient outcomes.

Market Sentiment Analysis

POSITIVE FACTORS

  • Acquisition enhances Stryker's peripheral vascular portfolio.
  • Integration of innovative IVL technology improves treatment options.
  • Stryker's scale and resources will support better patient outcomes.

Full Press Release Details

Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK announced that it has completed the acquisition of Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company developing a next-generation intravascular lithotripsy (IVL) platform designed to treat complex peripheral arterial disease.
“This acquisition is a significant milestone in expanding our peripheral vascular portfolio and enhancing our ability to address challenging arterial disease,” said Kevin Lobo, Chair and CEO, Stryker. “By integrating AVS’s innovative CO₂-generated pressure wave technology with Stryker’s scale and resources, we are well-positioned to deliver solutions that support physicians and patient outcomes.”
The addition of an IVL platform will strengthen Stryker’s impact in peripheral vascular solutions.

About Stryker

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available atwww.stryker.com.

AboutAmplitude Vascular Systems (AVS)

Amplitude Vascular Systems (AVS) is a medical device company based in Boston, Mass., focused on treating severely calcified arterial disease. AVS is backed by global investors including BioStar Capital, Cue Growth Partners, and others. It was founded in 2017 by Hitinder Gurm, M.D., Interventional Cardiologist and Chief Clinical Officer at the University of Michigan, and Robert Chisena, Ph.D., Chief Technical Officer at AVS. More information is available atwww.avspulse.com.

Contacts

For investor inquiries:Nick Mead, Vice President, Investor Relations at 269-385-2600 ornick.mead@stryker.com

For media inquiries:Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 orkim.montagnino@stryker.com

Frequently Asked Questions

What is the purpose of Stryker's acquisition?

The acquisition aims to enhance Stryker's peripheral vascular portfolio with advanced IVL technology.

What technology does Amplitude Vascular Systems develop?

Amplitude Vascular Systems develops a next-generation intravascular lithotripsy platform.

Who founded Amplitude Vascular Systems?

Amplitude was founded by Hitinder Gurm, M.D., and Robert Chisena, Ph.D.

How will the acquisition benefit patient outcomes?

The integration of AVS's technology is expected to improve treatment for complex arterial diseases.

Last updated: May 7, 2026